Azacitidine Teva® is indicated for treatment of patients with the following French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL)
I.V, S.C
Lyophilized Powder For Suspension For SC Injection/ Solution For IV Infusion
להתוויות ופירוט נוסף, נא לעיין בעלון של התכשיר
באתר משרד הבריאות.